Janus Henderson Group PLC trimmed its position in United Therapeutics Co. (NASDAQ:UTHR) by 31.1% in the first quarter, HoldingsChannel.com reports. The firm owned 13,673 shares of the biotechnology company’s stock after selling 6,172 shares during the quarter. Janus Henderson Group PLC’s holdings in United Therapeutics were worth $1,605,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. Louisiana State Employees Retirement System lifted its position in shares of United Therapeutics by 0.9% during the 1st quarter. Louisiana State Employees Retirement System now owns 11,700 shares of the biotechnology company’s stock valued at $1,373,000 after acquiring an additional 100 shares during the last quarter. First Mercantile Trust Co. lifted its position in shares of United Therapeutics by 47.8% during the 4th quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 110 shares during the last quarter. Arizona State Retirement System lifted its position in shares of United Therapeutics by 0.4% during the 1st quarter. Arizona State Retirement System now owns 31,395 shares of the biotechnology company’s stock valued at $3,685,000 after acquiring an additional 111 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of United Therapeutics by 384.9% during the 4th quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 204 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its position in shares of United Therapeutics by 13.2% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,799 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 210 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.
In other news, Director Christopher Patusky sold 3,370 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $110.75, for a total value of $373,227.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 8.20% of the stock is owned by corporate insiders.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.64 by ($13.96). The business had revenue of $362.70 million during the quarter, compared to analysts’ expectations of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. United Therapeutics’s revenue for the quarter was down 6.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.76 EPS. Sell-side analysts anticipate that United Therapeutics Co. will post -5.03 EPS for the current fiscal year.
A number of equities research analysts have recently commented on UTHR shares. TheStreet upgraded United Therapeutics from a “c+” rating to a “b-” rating in a research report on Monday, February 11th. BidaskClub downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 31st. Oppenheimer set a $160.00 price objective on United Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 26th. Wedbush set a $269.00 price objective on United Therapeutics and gave the company a “buy” rating in a research report on Monday, April 8th. Finally, LADENBURG THALM/SH SH set a $124.00 price objective on United Therapeutics and gave the company a “hold” rating in a research report on Thursday, February 28th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $129.00.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://dakotafinancialnews.com/2019/05/22/united-therapeutics-co-uthr-shares-sold-by-janus-henderson-group-plc.html.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Story: What is a Lock-Up Period?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.